人工膵臓装置システムの世界市場

人工膵臓装置システムの世界市場は2030年までに15億米ドルに達する見込み

2023年に4億5,900万米ドルと推定される人工膵臓装置システムの世界市場は、分析期間2023-2030年にCAGR 18.8%で成長し、2030年には15億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである閾値サスペンデッドデバイスシステムは、CAGR 18.8％を記録し、分析期間終了までに12億米ドルに達すると予測されます。コントロール・ツー・ターゲット（CTT）システム分野の成長率は、分析期間中CAGR19.7％と推定されます。

米国市場は1億2,690万米ドル、中国はCAGR17.8％で成長予測

米国の人工膵臓装置システム市場は、2023年に1億2,690万米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年にかけて17.8％のCAGRで成長し、2030年には2億3,020万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ16.5％と15.8％と予測されています。欧州では、ドイツがCAGR約13.6%で成長すると予測されています。

世界の人工膵臓装置システム市場- 主要動向と促進要因のまとめ

人工膵臓装置システムは糖尿病治療をどう変革するか？

人工膵臓装置システム（APDS）は、特に正確で継続的なインスリン管理を必要とする1型糖尿病患者にとって、糖尿病ケアの画期的な進歩として登場しました。これらのシステムは、持続グルコースモニター（CGM）とインスリンポンプおよび高度なアルゴリズムを統合し、健康な膵臓の機能を忠実に模倣することで、インスリン投与のプロセスを自動化します。最小限の手動介入でグルコースレベルを目標範囲内に維持することにより、APDSは糖尿病管理の負担を大幅に軽減し、患者の転帰の改善と生活の質の向上につながります。技術が進歩し続ける中、これらのシステムは、従来のインスリン投与法に比べて比類のない精度とコントロールを提供し、糖尿病治療の未来として歓迎されています。

人工膵臓システムの成功の原動力となっている技術革新とは？

人工膵臓装置システムの成功は、継続的な技術革新、特にセンサーの精度、アルゴリズムの高度化、シームレスな機器統合によって大きく後押しされてきました。最近のCGM技術の改善により、APDSの有効性にとって重要な要素である、少ない校正回数で高精度で信頼性の高いグルコース測定値を提供するセンサーが開発されました。グルコースの動向を予測し、インスリン分泌量をリアルタイムで自動的に調整できる高度なアルゴリズムにより、これらのシステムは身体のニーズへの応答性がさらに向上しています。インスリンとグルカゴンの両方を投与するデュアルホルモンシステムの開発は、運動中、病気中、その他の困難な状況下でのグルコースコントロールを強化する、有望な飛躍的進歩を示しています。これらの技術革新は、APDSの有効性を向上させただけでなく、より使いやすく、日常的に快適に使用できるようにしました。

人工膵臓システムの普及を後押しする新たな動向とは？

多くの新たな動向が人工膵臓装置システムの普及に拍車をかけており、より個別化され、利用しやすい糖尿病治療への幅広いシフトを反映しています。個別化医療の推進は、個々の患者のユニークなニーズに合わせたAPDSの開発につながり、これらのシステムをより効果的で使いやすいものにしています。遠隔医療や遠隔モニタリング機能の台頭も、APDSの普及に寄与しています。これらの技術により、直接訪問することなく、継続的なグルコースモニタリングやインスリン調整が可能になったからです。さらに、糖尿病管理機器に対する健康保険の適用範囲が拡大したことで、APDSがより多くの人々にとって利用しやすくなっています。特に若年層における1型糖尿病の有病率の増加は、長期的な健康転帰を改善し、血糖コントロール不良に伴うリスクを最小限に抑える手段として、これらのシステムに対する需要をさらに促進しています。

人工膵臓装置システム市場の成長を促進している要因は？

人工膵臓装置システム市場の成長は、糖尿病管理の将来を形作るいくつかの重要な要因によって促進されています。糖尿病、特に1型糖尿病の世界の有病率の上昇により、より正確で効果的なグルコース管理ソリューションに対する緊急のニーズが生まれています。持続グルコースモニタリング、インスリンポンプ、AI駆動アルゴリズムの技術的進歩により、APDSの性能と信頼性が大幅に向上し、患者とヘルスケアプロバイダーの双方にとって魅力的なものとなっています。遠隔医療サービスの拡大とウェアラブル健康技術の採用増加は、より便利で効果的な糖尿病管理オプションを提供することにより、市場をさらに押し上げています。さらに、小児糖尿病治療が重視されるようになったことで、より使いやすく侵襲性の低い機器の開発が推進され、市場の可能性が広がっています。ヘルスケアシステムが価値ベースのケアを優先し続ける中、患者の転帰を改善し、長期的な糖尿病管理コストを削減するAPDSの能力は、市場の成長をさらに促進すると予想されます。

調査対象企業の例（全47件）

• Beta Bionics, Inc.
• Bigfoot Biomedical, Inc.
• Johnson & Johnson
• Medtronic PLC
• Pancreum, Inc.
• Tandem Diabetes Care, Inc.
• TypeZero Technologies LLC

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• その他欧州
• アジア太平洋
• その他の地域

第4章 競合

Global Artificial Pancreas Device Systems Market to Reach US$1.5 Billion by 2030

The global market for Artificial Pancreas Device Systems estimated at US$459.0 Million in the year 2023, is expected to reach US$1.5 Billion by 2030, growing at a CAGR of 18.8% over the analysis period 2023-2030. Threshold Suspended Device Systems, one of the segments analyzed in the report, is expected to record a 18.8% CAGR and reach US$1.2 Billion by the end of the analysis period. Growth in the Control-to-Target (CTT) Systems segment is estimated at 19.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$126.9 Million While China is Forecast to Grow at 17.8% CAGR

The Artificial Pancreas Device Systems market in the U.S. is estimated at US$126.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$230.2 Million by the year 2030 trailing a CAGR of 17.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 16.5% and 15.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.6% CAGR.

Global Artificial Pancreas Device Systems Market - Key Trends and Drivers Summarized

How Are Artificial Pancreas Device Systems Transforming Diabetes Care?

Artificial pancreas device systems (APDS) have emerged as a groundbreaking advancement in diabetes care, particularly for those with Type 1 diabetes who require precise and continuous insulin management. These systems automate the process of insulin delivery by integrating continuous glucose monitors (CGMs) with insulin pumps and advanced algorithms, closely mimicking the function of a healthy pancreas. By maintaining glucose levels within a target range with minimal manual intervention, APDS significantly lighten the burden of diabetes management, leading to improved patient outcomes and an enhanced quality of life. As technology continues to advance, these systems are being hailed as the future of diabetes treatment, offering unmatched precision and control compared to traditional insulin administration methods.

What Technological Innovations Are Driving the Success of Artificial Pancreas Systems?

The success of artificial pancreas device systems has been largely driven by continuous technological innovations, particularly in sensor accuracy, algorithm sophistication, and seamless device integration. Recent improvements in CGM technology have resulted in sensors that provide highly accurate and reliable glucose readings with fewer calibrations, a critical component for the effectiveness of APDS. Advanced algorithms capable of predicting glucose trends and automatically adjusting insulin delivery in real-time have made these systems even more responsive to the body’s needs. The development of dual-hormone systems that administer both insulin and glucagon represents a promising leap forward, offering enhanced glucose control during exercise, illness, or other challenging conditions. These innovations have not only improved the efficacy of APDS but also made them more user-friendly and comfortable for everyday use.

What Emerging Trends Are Fueling the Adoption of Artificial Pancreas Systems?

A number of emerging trends are fueling the widespread adoption of artificial pancreas device systems, reflecting a broader shift toward more personalized and accessible diabetes care. The push for personalized medicine has led to the development of APDS tailored to the unique needs of individual patients, making these systems more effective and user-friendly. The rise of telemedicine and remote monitoring capabilities has also contributed to the growing popularity of APDS, as these technologies enable continuous glucose monitoring and insulin adjustments without the need for in-person visits. Additionally, expanded health insurance coverage for diabetes management devices is making APDS more accessible to a wider audience. The increasing prevalence of Type 1 diabetes, especially among younger populations, is further driving the demand for these systems as a means to improve long-term health outcomes and minimize the risks associated with poor glucose control.

Which Factors Are Fueling the Growth of the Artificial Pancreas Device Systems Market?

The growth in the artificial pancreas device systems market is fueled by several key factors that are shaping the future of diabetes management. The rising global prevalence of diabetes, particularly Type 1 diabetes, has created an urgent need for more precise and effective glucose management solutions. Technological advancements in continuous glucose monitoring, insulin pumps, and AI-driven algorithms have significantly improved the performance and reliability of APDS, making them more attractive to both patients and healthcare providers. The expansion of telehealth services and the increasing adoption of wearable health technologies are further boosting the market by providing more convenient and effective diabetes management options. Additionally, the growing emphasis on pediatric diabetes care is driving the development of more user-friendly and less invasive devices, broadening the market’s potential. As healthcare systems continue to prioritize value-based care, the ability of APDS to improve patient outcomes and reduce long-term diabetes management costs is expected to further propel the market’s growth.

Select Competitors (Total 47 Featured) -

• Beta Bionics, Inc.
• Bigfoot Biomedical, Inc.
• Johnson & Johnson
• Medtronic PLC
• Pancreum, Inc.
• Tandem Diabetes Care, Inc.
• TypeZero Technologies LLC

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • Artificial Pancreas Device Systems - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Diabetes Propels Growth in Artificial Pancreas Device Systems Market
  • Advancements in Continuous Glucose Monitoring (CGM) Drives Adoption
  • Integration of Insulin Pumps with Advanced Algorithms Expands Addressable Market Opportunity
  • Regulatory Approvals for Hybrid Closed-Loop Systems Propel Market Expansion
  • Improved Patient Outcomes with Automated Insulin Delivery Systems Spurs Growth
  • Increasing Adoption of Wearable Health Technology Drives Demand for Artificial Pancreas Devices
  • Innovation in Biocompatible Materials and Sensors Generates Opportunities for Enhanced Device Durability
  • Development of Dual-Hormone Systems Throws the Spotlight on Next-Generation Solutions
  • Rising Incidence of Type 1 Diabetes Among Youth Fuels Market Growth
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 2: World 7-Year Perspective for Artificial Pancreas Device Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
  • TABLE 3: World Artificial Pancreas Device Systems Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Threshold Suspended Device Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 5: World 7-Year Perspective for Threshold Suspended Device Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 6: World Recent Past, Current & Future Analysis for Control-to-Target (CTT) Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 7: World 7-Year Perspective for Control-to-Target (CTT) Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Control-to-Range (CTR) Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 9: World 7-Year Perspective for Control-to-Range (CTR) Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Artificial Pancreas Device Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 10: USA Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Device - Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 11: USA 7-Year Perspective for Artificial Pancreas Device Systems by Device - Percentage Breakdown of Value Sales for Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems for the Years 2024 & 2030
• CANADA
  • TABLE 12: Canada Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Device - Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 13: Canada 7-Year Perspective for Artificial Pancreas Device Systems by Device - Percentage Breakdown of Value Sales for Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems for the Years 2024 & 2030
• JAPAN
  • Artificial Pancreas Device Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 14: Japan Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Device - Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 15: Japan 7-Year Perspective for Artificial Pancreas Device Systems by Device - Percentage Breakdown of Value Sales for Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems for the Years 2024 & 2030
• CHINA
  • Artificial Pancreas Device Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 16: China Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Device - Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 17: China 7-Year Perspective for Artificial Pancreas Device Systems by Device - Percentage Breakdown of Value Sales for Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems for the Years 2024 & 2030
• EUROPE
  • Artificial Pancreas Device Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 18: Europe Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 19: Europe 7-Year Perspective for Artificial Pancreas Device Systems by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
  • TABLE 20: Europe Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Device - Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 21: Europe 7-Year Perspective for Artificial Pancreas Device Systems by Device - Percentage Breakdown of Value Sales for Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems for the Years 2024 & 2030
• FRANCE
  • Artificial Pancreas Device Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 22: France Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Device - Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 23: France 7-Year Perspective for Artificial Pancreas Device Systems by Device - Percentage Breakdown of Value Sales for Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems for the Years 2024 & 2030
• GERMANY
  • Artificial Pancreas Device Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 24: Germany Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Device - Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 25: Germany 7-Year Perspective for Artificial Pancreas Device Systems by Device - Percentage Breakdown of Value Sales for Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems for the Years 2024 & 2030
• ITALY
  • TABLE 26: Italy Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Device - Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 27: Italy 7-Year Perspective for Artificial Pancreas Device Systems by Device - Percentage Breakdown of Value Sales for Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems for the Years 2024 & 2030
• UNITED KINGDOM
  • Artificial Pancreas Device Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 28: UK Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Device - Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 29: UK 7-Year Perspective for Artificial Pancreas Device Systems by Device - Percentage Breakdown of Value Sales for Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems for the Years 2024 & 2030
• REST OF EUROPE
  • TABLE 30: Rest of Europe Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Device - Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 31: Rest of Europe 7-Year Perspective for Artificial Pancreas Device Systems by Device - Percentage Breakdown of Value Sales for Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems for the Years 2024 & 2030
• ASIA-PACIFIC
  • Artificial Pancreas Device Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 32: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Device - Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 33: Asia-Pacific 7-Year Perspective for Artificial Pancreas Device Systems by Device - Percentage Breakdown of Value Sales for Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems for the Years 2024 & 2030
• REST OF WORLD
  • TABLE 34: Rest of World Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Device - Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 35: Rest of World 7-Year Perspective for Artificial Pancreas Device Systems by Device - Percentage Breakdown of Value Sales for Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems for the Years 2024 & 2030

IV. COMPETITION